Biopharma lobbyists slam Obama budget as 'bad for innovation'
This article was originally published in Scrip
Executive Summary
To Washington lobbyists representing the biopharmaceutical industry, President Barack Obama's $3.77 trillion 2014 budget blueprint, which seeks to replace the sequester, is the glass half empty, if not more so, although the generic drug trade group embraced the White House proposal to reduce from 12 years to seven the exclusivity protection innovator biologics have against biosimilars.